UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K/A
(AMENDMENT NO. 2)



CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2026


LISATA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)


Delaware
001-33650
22-2343568
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

P.O. Box 173 Liberty Corner, NJ 07938
(Address of principal executive offices, including zip code)

(908) 842-0100
(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trade
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.001 par value per share
 
LSTA
 
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company  ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



Explanatory Note
 
This Amendment No. 2 on Form 8-K/A (this “Amendment No. 2”) amends the Current Report on Form 8-K filed by Lisata Therapeutics, Inc. (the “Company”) on September 17, 2026 in which the Company reported, among other events, the completion of the acquisition of Marea Therapeutics, Inc., a Delaware corporation (“Marea”), as further amended by Amendment No. 1 on Form 8-K/A which was filed by the Company with the SEC on November 12, 2026 to include the financial statements required by Item 9.01(a) of Form 8-K and the pro forma financial information required by Item 9.01(b) of Form 8-K (the “Original Report”).
 
This Amendment No. 2 to the Original Report is being filed solely to amend Item 9.01 of the Original Report to include the unaudited pro forma combined statement of operations of the Company for the nine months ended September 30, 2026 and the year ended December 31, 2025 in connection with the filing of a registration statement on Form S-3 by the Company. Except as provided herein, the disclosures made in the Original Report remain unchanged.
 
In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended, the complete text of Item 9.01 (as amended) is included herein.
 
Item 9.01 - Financial Statements and Exhibits.
 
(a)
Financial statements of business acquired
 
The audited combined financial statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. as of and for the years ended December 31, 2025 and 2024 and the related notes thereto have been audited by Ernst & Young LLP, Marea’s independent auditors, as set forth in its report thereon, and are incorporated by reference to Exhibit 99.3 from the Registrant’s Amendment No. 1 to Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026.
 
The unaudited condensed combined interim financial statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. as of June 30, 2026 and December 31, 2025 and for the six months ended June 30, 2026 and 2025 and the related notes thereto are incorporated by reference to Exhibit 99.4 from the Registrant’s Amendment No. 1 to Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026.
 
(b)
Pro forma financial information
 
The unaudited pro forma combined financial information of the Company as of and for the six months ended June 30, 2026 and the year ended December 31, 2025 is incorporated by reference to Exhibit 99.5 from the Registrant’s Amendment No. 1 to Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026.
 
The unaudited pro forma condensed combined statement of operations of the Company for the nine months ended September 30, 2026 based on (i) the historical unaudited condensed statement of operations of the Company for the nine months ended September 30, 2026 and (ii) the historical unaudited condensed statement of operations of Marea for the period January 1, 2026 through September 17, 2026, as well as the unaudited pro forma condensed combined statement of operations of the Company for the year ended December 31, 2025, as adjusted to give effect to the Company’s acquisition of Marea as if it had occurred on January 1, 2025, are attached hereto as Exhibit 99.6 and incorporated herein by reference.
 
(d)
Exhibits

Exhibit
Number
 
 
Description
     
 
Agreement and Plan of Merger, dated September 17, 2026, by and among Lisata Therapeutics, Inc., Mariner Merger Sub I, Inc., Mariner Merger Sub II, LLC and Marea Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
     
 
Certificate of Designation of Series C Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).


 
Form of Marea Stockholders Registration Rights Agreement, by and among Lisata Therapeutics, Inc. and certain Marea stockholders (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
     
 
Form of Securities Purchase Agreement, dated as of September 17, 2026, by and among Lisata Therapeutics, Inc. and each investor listed on Exhibit A thereto (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
     
 
Form of Registration Rights Agreement, by and among Lisata Therapeutics, Inc. and certain investors signatory thereto (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
     
 
Consent of Ernst & Young LLP, Independent Auditors (incorporated by reference to Exhibit 23.1 from the Registrant’s Amendment No. 1 to Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026).
     
 
Press Release issued on September 17, 2026 (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
     
 
Presentation made available to the Investors by Lisata Therapeutics, Inc. and Marea Therapeutics, Inc. on September 17, 2026 (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
     
 
Audited Combined Financial Statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. as of and for the year ended December 31, 2025 and 2024 and the related notes thereto (incorporated by reference to Exhibit 99.3 from the Registrant’s Amendment No. 1 to Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026).
     
 
Unaudited Condensed Combined Interim Financial Statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. as of June 30, 2026 and December 31, 2025 and for the six months ended June 30, 2026 and 2025 and the related notes thereto (incorporated by reference to Exhibit 99.4 from the Registrant’s Amendment No. 1 to Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026).
     
 
Unaudited Pro Forma Condensed Combined Financial Information of the Company as of and for the six months ended June 30, 2026 and the year ended December 31, 2025 (incorporated by reference to Exhibit 99.5 from the Registrant’s Amendment No. 1 to Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026).
     
 
Unaudited Pro Forma Condensed Combined Statement of Operations of the Company for the nine months ended September 30, 2026 and the year ended December 31, 2025.
     
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)

(1) Certain schedules and attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to provide, on a supplemental basis, a copy of any omitted schedules and attachments to the Securities and Exchange Commission or its staff upon request.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Lisata Therapeutics, Inc.
     
Date: November 19, 2026
By:
/s/ David J. Mazzo, Ph.D.
   
David J. Mazzo, Ph.D.
   
Chief Executive Officer